Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Neuroendocrinology. 2016 Apr 15;104(2):194–208. doi: 10.1159/000446114

Figure 2. CUMS impairs GABAA-mediated inhibition in the PVN.

Figure 2

(A): Both 11-day CUMS treatment and 20-day CUMS treatment significantly increased circulating CORT levels. (n = 8 rats for 11-day CUMS and n = 6 rats for 20-day CUMS, P < 0.05, repeated-measures ANOVA with Dunnett's post hoc test). (B): CUMS significantly suppressed sucrose preference (n = 8 rats in each group, P < 0.05, paired t test). (C): Change in circulating CORT levels after microinjection of the GABAA antagonist gabazine into the PVN (n = 6 rats in each group, * P < 0.05 compared with the basal value, repeated-measures ANOVA with Dunnett's post hoc test, # P < 0.05 compared with values in unstressed group, unpaired t test). (D): Photomicrographic images depict the microinfusion sites marked by fluorescent microspheres (0.04 μm, wavelength 580 nm) in the PVN in light optics (a) and fluorescent illumination (b). 3V, third ventricle. All data are expressed as mean ± s.e.m.